Bladder Cancer - Pipeline Review, H1 2012

Global Markets Direct, February 2012, Pages: 425

Bladder Cancer – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Bladder Cancer - Pipeline Review, H1 2012', provides an overview of the Bladder Cancer therapeutic pipeline. This report provides information on the therapeutic development for Bladder Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bladder Cancer. 'Bladder Cancer - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bladder Cancer.
- A review of the Bladder Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bladder Cancer pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bladder Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bladder Cancer pipeline depth and focus of Bladder Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Bladder Cancer Therapeutic Products under Development, Key Players in Bladder Cancer Therapeutics, Bladder Cancer Pipeline Overview, Bladder Cancer Pipeline, Bladder Cancer Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Bladder Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Bladder Cancer
Bladder Cancer Therapeutics under Development by Companies
Bladder Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Bladder Cancer Therapeutics – Products under Development by Companies
Bladder Cancer Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Bladder Cancer Therapeutics Development
Shionogi & Co., Ltd.
Sanofi-Aventis
Viralytics Ltd.
Seattle Genetics, Inc.
Bioniche Life Sciences, Inc.
ImClone Systems Incorporated
Eisai Co., Ltd.
Genta Incorporated
MDRNA, Inc.
Celgene Corporation
Halozyme Therapeutics
Celldex Therapeutics, Inc.
AEterna Zentaris Inc.
Lorus Therapeutics Inc
Oncolytics Biotech Inc.
Allos Therapeutics, Inc
TopoTarget A/S
Oncogenex Pharmaceuticals, Inc.
Dendreon Corporation
Sanochemia Pharmazeutika AG
OncoTherapy Science, Inc.
PCI Biotech Holding ASA
Spectrum Pharmaceuticals, Inc.
Acceleron Pharma, Inc.
Med Discovery SA
Altor BioScience Corporation
Telormedix SA
MacroGenics, Inc.
Stemline Therapeutics, Inc.
BioCancell Therapeutics, Inc.
Polyphenon Pharma
AndroScience Corporation
PharmaMar, S.A.
Viventia Biotechnologies Inc.
TRACON Pharmaceuticals, Inc.
Targa Therapeutics Corp.
Cytavis Biopharma GmbH
Bladder Cancer – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AEZS-108 - Drug Profile
IMC-18F1 - Drug Profile
Tesetaxel - Drug Profile
OGX-427 - Drug Profile
CDX-1401 - Drug Profile
Sotatercept - Drug Profile
Chemophase - Drug Profile
LOR-2040 - Drug Profile
MDRG01 - Drug Profile
MDP01 - Drug Profile
Abraxane - Drug Profile
Urocidin - Drug Profile
OGX-225 - Drug Profile
SL-601 - Drug Profile
PVP Hypericin - Drug Profile
ASC-ST.Z1 - Drug Profile
Polyphenon E - Drug Profile
Eoquin - Drug Profile
ALT-801 - Drug Profile
TMX-101 - Drug Profile
TMX-202 - Drug Profile
BC-819 - Drug Profile
BC-821 - Drug Profile
Folotyn - Drug Profile
Recombinant Interferon Alfa - Drug Profile
SCH 721015 + SCH 209702 - Drug Profile
Vicinium - Drug Profile
NY-ESO-1 Peptide Vaccine + BCG Vaccine + Sargramostim - Drug Profile
DEPDC1 + MPHOSH1 - Drug Profile
CG0070 - Drug Profile
B5860N - Drug Profile
C2093 - Drug Profile
BAY 43-9006 - Drug Profile
Piritrexim - Drug Profile
Taxotere - Drug Profile
Oxaliplatin + Taxotere - Drug Profile
5-Fluorouracil - Drug Profile
Gemcitabine Hydrochloride - Drug Profile
Belinostat + Carboplatin + Paclitaxel - Drug Profile
gemictabine + paclitaxel - Drug Profile
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
OGX-427 + Docetaxel - Drug Profile
TRC105 - Drug Profile
Larotaxel + Cisplatin - Drug Profile
Docetaxel + Cisplatin + Gemcitabine + Methotrexate - Drug Profile
BCG Vaccine + Iressa - Drug Profile
Sutent - Drug Profile
Fluorouracil + Mitomycin C + Radiation Therapy - Drug Profile
Methotrexate + Vinblastine + Doxorubicin + Cisplatin + Gemcitabine - Drug Profile
mTOR/PTEN Bladder Cancer Program - Drug Profile
Gemcitabine + Cisplatin + Sorafenib - Drug Profile
rAd-IFN - Drug Profile
5-Fluorouracil + Cisplatin + Radiation Therapy - Drug Profile
Cisplatin + Fluorouracil + Radiation Theraphy - Drug Profile
Cisplatin + Radiotherapy - Drug Profile
Sutent - Drug Profile
Carboplatin - Drug Profile
Sunitinib - Drug Profile
BCG Vaccine + Mitomycin C - Drug Profile
Carboplatin + Methotrexate + Vinblastine - Drug Profile
Cisplatin + Gemcitabine + Lapatinib - Drug Profile
Cisplatin + Doxorubicin + Gemcitabine + Methotrexate + Vinblastine + Filgrastim - Drug Profile
Pazopanib - Drug Profile
Everolimus + Paclitaxel - Drug Profile
Gemzar + Cisplatin + Radiation Therapy - Drug Profile
Gemcitabine + Paclitaxel + Doxorubicin + Pegfilgrastim - Drug Profile
Gemcitabine + Cisplatin - Drug Profile
Cisplatin + Gemcitabine + Sorafenib - Drug Profile
Thiotepa - Drug Profile
Pirarubicin - Drug Profile
ALT-803 - Drug Profile
Tyverb - Drug Profile
Bacillus Calmette-Guerin Vaccine - Drug Profile
Gemcitabine Hydrochloride + Doxorubicin + Paclitaxel + Cisplatin + Filgrastim - Drug Profile
Doxorubicin + Gemcitabine + Paclitaxel + Cisplatin + Ifosfamide + Filgrastim - Drug Profile
Aminophylline + BCG - Drug Profile
MGA271 - Drug Profile
PC-A22 - Drug Profile
Pirarubicin - Drug Profile
ABT-888 + Cisplatin + Gemcitabine Hydrochloride - Drug Profile
Sutent - Drug Profile
ALT-801 + Gemcitabine + Cisplatin - Drug Profile
TD6989 - Drug Profile
TD3633 - Drug Profile
TD1770 - Drug Profile
Gemcitabine + Carboplatin + Lenalidomide - Drug Profile
DN24-02 - Drug Profile
Glycosylated Recombinant Human Interleukin-7 - Drug Profile
Neo-Bladder Replacement - Drug Profile
Gemcitabine + Cisplatin + Panitumumab - Drug Profile
Pazopanib + Vinflunine - Drug Profile
ASG-22ME - Drug Profile
Gemcitabine + Radiation Therapy - Drug Profile
VEGF/rGel - Drug Profile
recMAGE-A3 + AS15 - Drug Profile
OGX-427 + Gemcitabine + Cisplatin - Drug Profile
BO-110 - Drug Profile
ONS-1015 - Drug Profile
CEL-031 - Drug Profile
CEL-031 - Drug Profile
Bladder Cancer Therapeutics – Drug Profile Updates
Bladder Cancer Therapeutics – Discontinued Products
Bladder Cancer Therapeutics - Dormant Products
Bladder Cancer – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Bladder Cancer, H1 2012
Products under Development for Bladder Cancer – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Number of Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012
Products under Investigation by Universities/Institutes, H1 2012 (Contd..1)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..2)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..3)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..5)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..6)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..7)
Products under Investigation by Universities/Institutes, H1 2012 (Contd..8)
Shionogi & Co., Ltd., H1 2012
Sanofi-Aventis, H1 2012
Viralytics Ltd., H1 2012
Seattle Genetics, Inc., H1 2012
Bioniche Life Sciences, Inc., H1 2012
ImClone Systems Incorporated, H1 2012
Eisai Co., Ltd., H1 2012
Genta Incorporated, H1 2012
MDRNA, Inc., H1 2012
Celgene Corporation, H1 2012
Halozyme Therapeutics, H1 2012
Celldex Therapeutics, Inc., H1 2012
AEterna Zentaris Inc., H1 2012
Lorus Therapeutics Inc, H1 2012
Oncolytics Biotech Inc., H1 2012
Allos Therapeutics, Inc, H1 2012
TopoTarget A/S, H1 2012
Oncogenex Pharmaceuticals, Inc., H1 2012
Dendreon Corporation, H1 2012
Sanochemia Pharmazeutika AG, H1 2012
OncoTherapy Science, Inc., H1 2012
PCI Biotech Holding ASA, H1 2012
Spectrum Pharmaceuticals, Inc., H1 2012
Acceleron Pharma, Inc., H1 2012
Med Discovery SA, H1 2012
Altor BioScience Corporation, H1 2012
Telormedix SA, H1 2012
MacroGenics, Inc., H1 2012
Stemline Therapeutics, Inc., H1 2012
BioCancell Therapeutics, Inc., H1 2012
Polyphenon Pharma, H1 2012
AndroScience Corporation, H1 2012
PharmaMar, S.A., H1 2012
Viventia Biotechnologies Inc., H1 2012
TRACON Pharmaceuticals, Inc., H1 2012
Targa Therapeutics Corp., H1 2012
Cytavis Biopharma GmbH, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Bladder Cancer Therapeutics – Drug Profile Updates
Bladder Cancer Therapeutics – Discontinued Products
Bladder Cancer Therapeutics – Discontinued Products (Contd..1)
Bladder Cancer Therapeutics – Dormant Products
Bladder Cancer Therapeutics – Dormant Products (Contd..1)
Bladder Cancer Therapeutics – Dormant Products (Contd..2)
Bladder Cancer Therapeutics – Dormant Products (Contd..3)
Bladder Cancer Therapeutics – Dormant Products (Contd..4)
Bladder Cancer Therapeutics – Dormant Products (Contd..5)
Bladder Cancer Therapeutics – Dormant Products (Contd..6)
Bladder Cancer Therapeutics – Dormant Products (Contd..7)
Bladder Cancer Therapeutics – Dormant Products (Contd..8)

List of Figures
Number of Products under Development for Bladder Cancer, H1 2012
Products under Development for Bladder Cancer – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Customers who bought this item also bought

• Bladder Cancer - Pipeline Review, H2 2012
• Interstitial Cystitis (Painful Bladder Syndrome) - Pipeline Review, H1 2013
• Chemotherapy Effects – Pipeline Review, H1 2013
• Alzheimer's Disease – Pipeline Review, H1 2013
• Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2013
• Overactive Bladder - Pipeline Review, H1 2012
• Obesity - Pipeline Review, H1 2013
• Eczema - Pipeline Review, H1 2013
• Rheumatoid Arthritis - Pipeline Review, H1 2013
• Osteoporosis - Pipeline Review, H1 2013